GT Biopharma(GTBP)

Focus: GT Biopharma is a public biotech company specializing in antioxidant therapeutics and antibodies, with a pipeline spanning oncology (GammaTile for brain tumors) and metabolic diseases (obesity and diabetes via magnetic systems). The company operates at a modest scale with minimal revenue generation and a lean R&D budget of $6M annually.

Metabolic Diseases Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About GT Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow GT Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GammaTile

Brain Tumor, Recurrent

N/A

Magnet System

Gastric Outlet Obstruction

N/A

Magnet System

Help build intelligence for GT Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology programs with recent FDA IND clearance for solid tumors (GTB-5550, May 2026) signal active clinical advancement in immuno-oncology.
GammaTile shows Phase 3/4 data for glioblastoma and brain metastases, representing a potentially differentiated surgical-targeted radiation approach.
Founded in 1999 with public status provides long-term credibility and potential for equity appreciation if pipeline candidates advance.

Watch Out For

Severe cash constraints ($4M FY2025, $1M FY2024) and mounting losses ($13.2M net loss FY2025) create near-term survival risk and probable dilutive financing rounds.
Zero active job openings and no disclosed headcount suggest organizational paralysis or transition; minimal hiring visibility means limited growth opportunities.
Pipeline diversity masks execution risk: 23 programs listed but only 2 active clinical trials and 5 publications suggest early-stage programs lack depth and most remain preclinical.

Generated by Claude from GT Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GTU Artificial Urinary Sphincter

Male Stress Urinary Incontinence

N/A

Clinical Trials (1)

NCT02288455Clinical Investigation of GT UrologIcal, LLC's Artificial Urinary Sphincter (RELIEF II)

N/A

Side-to-side duodenal-ileal anastomosis

Anastomosis, Surgical

N/A

GammaTile seed loader

Central Nervous System Lesion

N/A